{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T07:12:56Z","timestamp":1766733176367},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.ccc.2006.02.002","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:08:25Z","timestamp":1168441705000},"page":"347-355","source":"Crossref","is-referenced-by-count":27,"title":["Drug-Associated Disease: Hematologic Dysfunction"],"prefix":"10.1016","volume":"22","author":[{"given":"Erik R.","family":"Vandendries","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed E.","family":"Drews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccc.2006.02.002_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.1996.tb01641.x","article-title":"Drugs in the aetiology of agranulocytosis and aplastic anaemia","volume":"60","author":"Kaufman","year":"1996","journal-title":"Eur J Haematol Suppl"},{"issue":"7","key":"10.1016\/j.ccc.2006.02.002_bib2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.7326\/0003-4819-136-7-200204020-00011","article-title":"Acquired aplastic anemia","volume":"136","author":"Young","year":"2002","journal-title":"Ann Intern Med"},{"issue":"6020","key":"10.1016\/j.ccc.2006.02.002_bib3","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/bmj.1.6020.1266","article-title":"Myelotoxicity of gold","volume":"1","author":"Kay","year":"1976","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ccc.2006.02.002_bib4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1001\/jama.1969.03160110017004","article-title":"Statewide study of chloramphenicol therapy and fatal aplastic anemia","volume":"208","author":"Wallerstein","year":"1969","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccc.2006.02.002_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1365-2141.2002.03588.x","article-title":"Reduced function of the multidrug resistance P-glycoprotein in CD34+ cells of patients with aplastic anaemia","volume":"118","author":"Calado","year":"2002","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ccc.2006.02.002_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0145-2126(92)90102-D","article-title":"Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review","volume":"16","author":"Pedersen-Bjergaard","year":"1992","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.ccc.2006.02.002_bib7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bmt.1701781","article-title":"Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation","volume":"23","author":"Sobecks","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.ccc.2006.02.002_bib8","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","article-title":"Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus","volume":"91","author":"Relling","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ccc.2006.02.002_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","article-title":"Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome","volume":"68","author":"Harris","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ccc.2006.02.002_bib10","first-page":"477","article-title":"Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"2","author":"Takimoto","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ccc.2006.02.002_bib11","first-page":"3021","article-title":"Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity","volume":"9","author":"Ezzeldin","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ccc.2006.02.002_bib12","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1172\/JCI117840","article-title":"Cisplatin-associated anemia: an erythropoietin deficiency syndrome","volume":"95","author":"Wood","year":"1995","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.ccc.2006.02.002_bib13","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood-2005-02-0508","article-title":"Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"106","author":"Bennett","year":"2005","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ccc.2006.02.002_bib14","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa040528","article-title":"Pure red-cell aplasia and epoetin therapy","volume":"351","author":"Bennett","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ccc.2006.02.002_bib15","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/j.1523-1755.2005.00340.x","article-title":"The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes","volume":"67","author":"Boven","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ccc.2006.02.002_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tox.2004.12.031","article-title":"Drug-induced immune cytopenias","volume":"209","author":"Aster","year":"2005","journal-title":"Toxicology"},{"issue":"5","key":"10.1016\/j.ccc.2006.02.002_bib17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00062752-200109000-00005","article-title":"Molecular mechanisms of drug-induced thrombocytopenia","volume":"8","author":"Burgess","year":"2001","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.ccc.2006.02.002_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/asheducation-2004.1.63","article-title":"Congenital and acquired neutropenia","author":"Berliner","year":"2004","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"5","key":"10.1016\/j.ccc.2006.02.002_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1537-2995.1999.39050527.x","article-title":"Demonstration of drug-dependent antibodies in two patients with neutropenia and successful treatment with granulocyte-colony-stimulating factor","volume":"39","author":"Meyer","year":"1999","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.ccc.2006.02.002_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.1989.tb07672.x","article-title":"Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies","volume":"72","author":"Salama","year":"1989","journal-title":"Br J Haematol"},{"issue":"4 Suppl","key":"10.1016\/j.ccc.2006.02.002_bib21","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.1378\/chest.108.4_Supplement.258S","article-title":"Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"108","author":"Hirsh","year":"1995","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1016\/j.ccc.2006.02.002_bib22","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1378\/chest.127.2_suppl.35S","article-title":"New approaches to the diagnosis of heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"2005","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ccc.2006.02.002_bib23","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJM200303133481120","article-title":"Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin","volume":"348","author":"Warkentin","year":"2003","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ccc.2006.02.002_bib24","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1161\/01.CIR.0000147537.72829.1B","article-title":"Heparin-induced thrombocytopenia: diagnosis and management","volume":"110","author":"Warkentin","year":"2004","journal-title":"Circulation"},{"issue":"Suppl 8A","key":"10.1016\/j.ccc.2006.02.002_bib25","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/j.amjmed.2005.06.005","article-title":"Heparin-induced thrombocytopenia: clinical manifestations and management strategies","volume":"118","author":"Menajovsky","year":"2005","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ccc.2006.02.002_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2004-05-2010","article-title":"Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin","volume":"105","author":"Savi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ccc.2006.02.002_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ccc.2006.02.002_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-0968.2003.00127.x","article-title":"Drug-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a concise review","volume":"8","author":"Dlott","year":"2004","journal-title":"Ther Apher Dial"},{"issue":"2","key":"10.1016\/j.ccc.2006.02.002_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1526-0968.2003.00113.x","article-title":"Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow","volume":"8","author":"McCarthy","year":"2004","journal-title":"Ther Apher Dial"},{"issue":"24","key":"10.1016\/j.ccc.2006.02.002_bib30","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel","volume":"342","author":"Bennett","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ccc.2006.02.002_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-128-7-199804010-00004","article-title":"Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases","volume":"128","author":"Bennett","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccc.2006.02.002_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.57.061804.084505","article-title":"Current concepts in thrombotic thrombocytopenic purpura","volume":"57","author":"Tsai","year":"2006","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.ccc.2006.02.002_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"8","author":"Medina","year":"2001","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.ccc.2006.02.002_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","article-title":"Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy","volume":"101","author":"Jackson","year":"1984","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.ccc.2006.02.002_bib35","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/1097-0142(19941201)74:11<3059::AID-CNCR2820741125>3.0.CO;2-Z","article-title":"Cisplatin-associated hemolytic uremic syndrome","volume":"74","author":"Canpolat","year":"1994","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ccc.2006.02.002_bib36","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"issue":"3 Suppl","key":"10.1016\/j.ccc.2006.02.002_bib37","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","article-title":"Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Levine","year":"2004","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccc.2006.02.002_bib38","first-page":"S11","article-title":"Reversing anticoagulants both old and new","volume":"49","author":"Warkentin","year":"2002","journal-title":"Can J Anaesth"},{"issue":"6","key":"10.1016\/j.ccc.2006.02.002_bib39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0025-6196(11)62639-6","article-title":"Recombinant activated factor VII for treatment of enoxaparin-induced bleeding","volume":"79","author":"Hu","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.ccc.2006.02.002_bib40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4065\/79.12.1495","article-title":"Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage","volume":"79","author":"Freeman","year":"2004","journal-title":"Mayo Clin Proc"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070406000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070406000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:57:52Z","timestamp":1707526672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070406000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0749070406000030"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2006.02.002","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}